Menu Search
Equities

Incyte Corp

INCY:NSQ

Incyte Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)53.11
  • Today's Change0.17 / 0.32%
  • Shares traded546.23k
  • 1 Year change-24.09%
  • Beta0.6879
Data delayed at least 15 minutes, as of May 02 2024 17:20 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Incyte Corp grew net income 75.42% from 340.66m to 597.60m primarily through revenue growth (3.39bn to 3.70bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 8.87% growth in revenues contributed enough to still see net income improve.
Gross margin93.71%
Net profit margin16.17%
Operating margin16.79%
Return on assets9.47%
Return on equity12.50%
Return on investment11.69%
More ▼

Cash flow in USDView more

In 2023, Incyte Corp increased its cash reserves by 8.88%, or 262.10m. The company earned 496.49m from its operations for a Cash Flow Margin of 13.43%. In addition the company used 207.68m on investing activities and also paid 20.03m in financing cash flows.
Cash flow per share3.01
Price/Cash flow per share17.08
Book value per share23.14
Tangible book value per share21.89
More ▼

Balance sheet in USDView more

Incyte Corp has a strong Balance Sheet and has consistently grown its cash reserves over the last four years to total 3.21bn.
Current ratio3.75
Quick ratio3.69
Total debt/total equity0.0063
Total debt/total capital0.0062
More ▼

Growth rates in USD

Growth rate information is not available.
EPS growth(5 years)39.11
EPS (TTM) vs
TTM 1 year ago		73.71
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.